Dec. 03, 2019: Immunomedics,a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC) announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in quest of accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC).
If sacituzumab govitecan approved, it could become an important new treatment option for patients with late-stage mTNBC. https://fda.einnews.com/pr_news/503880625/immunomedics-resubmits-biologics-license-application-to-the-fda-for-sacituzumab-govitecan
